Prazosin Metabolism: Liver
Prazosin is metabolized primarily in the liver, not the kidneys. The drug undergoes extensive hepatic metabolism through demethylation and conjugation pathways, with metabolites then excreted mainly via bile and feces 1.
Metabolic Pathways
According to FDA labeling, prazosin is extensively metabolized by the liver, primarily through:
- O-demethylation (6- or 7-position demethylation)
- Conjugation reactions (particularly glucuronidation)
- N-dealkylation (to a lesser extent)
The metabolites are then excreted predominantly through biliary secretion into feces, with less than 6% of unchanged prazosin appearing in urine 1, 2.
Clinical Implications
Renal Impairment
- No dose adjustment needed for renal dysfunction
- The kidneys play minimal role in prazosin elimination
- The drug is not dialyzable because it is highly protein-bound (92-97%) 1
Hepatic Impairment
- Dose reduction may be necessary in severe liver dysfunction
- Patients with severe hepatic dysfunction show approximately 50% lower clearance compared to those with normal liver function 3
- The elimination half-life is prolonged in liver disease
Pharmacokinetic Details
The drug demonstrates:
- High first-pass metabolism in the liver
- Oral bioavailability of approximately 56.9% (range 43.5-69.3%) due to extensive hepatic extraction 3
- Plasma half-life of 2-3 hours in normal patients 1
- High protein binding (92-97%) to albumin and alpha-1-acid glycoprotein 3
Common Pitfall
Do not confuse prazosin with renally-cleared alpha-blockers or assume all antihypertensives require renal dose adjustment. Prazosin's hepatic metabolism makes it relatively safe in renal disease but requires caution in hepatic impairment—the opposite of many other cardiovascular medications.